T.V. Kashnikova, E.A. Druz, N.D. Luzhnov, E.V. Lutsenko, N.B. Feldman, S.V. Lutsenko, V.A. Bikov

A non-covalent complex of albumin with silymarin with molar ratio of components 1:4 that is suitable for parenteral administration was established. Unlike native silymarine possessing low solubility, silymarine in complex with albumin is suitable for parenteral use in therapeutic doses. The research of hepatoprotective properties of the preparation in comparison with free silymarin and albumin was conducted in mice with acute toxic hepatitis caused by CCl4 intake. The dose of silymarine in complex with albumin used intravenously (5 mg/kg) was 10 times lower then dose of native silymarine used for oral intake. It was shown that the complex promoted the decrease of hepatitis marker enzymes and the content of total bilirubin in blood serum of experimental animals with model acute toxic hepatitis: AST - in 41,2%, ALT - in 55,4%, GGT - in 91,3%, ALP - in 36,9%, total bilirubin - in 85,5%. The complex application also improved the survival and contributed normalization of liver weight. Free silymarin and albumin in the doses used didn-t have a significant influence on the activities of hepatitis marker enzymes. It has been also demonstrated in morphological studies that the complex of albumin with silymarin promoted the increase of hepatic cells functional activity and the decrease of inflammatory processes and dystrophic changes in liver.